Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

Inclusion Criteria: * \- Chinese subjects at least 18 years of age. * \- Chronic Kidney Disease (CKD) stage 3 and 4. * \- Mean of 2 measurement of serum potassium higher than 5.0 and lower than 6.5 mEq/L at baseline. * \- Subjects on any stable dose of at least 1 RAASi medication for at least 28 days before Day 0/baseline. * \- If on antihypertensive medication, have a stable dose for 28 days before Day 0/baseline. * \- Women of childbearing potential must agree to continue using contraception throughout the study and for 4 weeks after study completion. Exclusion Criteria: * \- Any level of hyperkalemia at Day 0/baseline that, in the opinion of the Investigator, requires emergency intervention. * \- Type 1 diabetes or Type 2 diabetes mellitus with glycated haemoglobin (Hb A1c) higher than 10.0% at screening/Part A baseline. * \- History of acute renal insufficiency in the past 3 months prior to the beginning of the study. * \- Diseases affecting the hearth muscle and heart's ability to pump blood around the body * \- Major surgery including thoracic and cardiac within 3 months prior to the beginning of the study or anticipated need during study participation. * \- Heart or kidney transplant recipient or anticipated need for transplant during study participation * \- Diagnosis or treatment of a malignancy in the past 2 years before Day 0/baseline. * \- Use of potassium supplements, bicarbonate or baking soda in the last 7 days prior to Day 0/baseline. * \- Pregnant women or…